ArticleP & T : a peer-reviewed journal for formulary management2013

The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.

Jack McCainPubMed ↗Full text ↗

No numbers read from the abstract.